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Abstract 1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroiso-
quinoline (salsolinol) is a well-known endogenous compound
that has been proposed as a factor involved in the patho-
genesis of Parkinson’s disease. In the present study, we in-
vestigated the impact of acute and chronic salsolinol
(100 mg.kg i.p.) administration on L-DOPA-induced loco-
motor hyperactivity and neurochemical changes (the dopa-
mine level and its metabolism in rat brain structures).
Moreover, using the in vivo microdialysis technique, we
measured the effect of acute and chronic salsolinol injection
on L-DOPA-induced dopamine release in the rat striatum. The
behavioral data demonstrated that both acute and chronic
salsolinol administration antagonized L-DOPA-mediated
hyperactivity. An ex vivo neurochemical experiment indi-
cated that chronic but not acute salsolinol administration
partially inhibited the L-DOPA-induced increases in the
concentration of dopamine and all of its metabolites in
dopaminergic structures. Additionally, the in vivo dopamine
release data obtained from the microdialysis experiments
clearly indicated that the differences in the effect of salsolinol
on the activities of L-DOPA depended on the mode of sal-
solinol treatment. Acute injection of salsolinol enhanced the
L-DOPA-induced elevation of dopamine release (by
*1200 %; P \ 0.01), whereas chronic administration of
salsolinol completely blocked the L-DOPA-induced elevation
of dopamine release in the rat striatum. These data demon-
strated that chronic administration of salsolinol significantly
impaired the response of dopaminergic neurons to L-DOPA
administration. In conclusion, we propose that an elevated
salsolinol level in parkinsonian patients may represent a se-
rious risk factor of the clinical efficacy of L-DOPA therapy.
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Introduction
The primary pathological process that characterizes
Parkinson’s disease (PD) is the progressive degeneration of
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dopaminergic neurons in the nigro-striatal pathway. This
process leads to a dramatic decrease in the dopamine con-
centration in the substantia nigra. The classical cardinal signs
of PD are rigidity, bradykinesia, resting tremor, and postural
instability. Oral administration of the dopamine precursor L-
DOPA has become the gold standard for the treatment of PD.
Although available medications provide some symptomatic
relief to nearly all patients, none of these drugs have been
shown to significantly slow or halt disease progression (Lang
2009; Fernandez 2012). Recent investigations of PD etio-
pathology suggest that the neurodegeneration that occurs in
this disease involves several cellular and molecular events,
such as oxidative stress, microglia-mediated inflammation,
and proapoptotic mechanisms (von Bohlen et al. 2004).
1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline
(salsolinol) is an endogenous tetrahydroisoquinoline deriva-
tive which has been found to induce slowly developing neu-
rodegenerative changes (Lorenc-Koci et al. 2008; Wa˛sik et al.
2009, 2014). In vivo, salsolinol can be formed in the mam-
malian brain via different mechanisms, e.g., the selective
synthesis of salsolinol from dopamine and acetaldehyde by
salsolinol synthase (Maruyama et al. 1997; Naoi et al. 1996).
Salsolinol is present in the human brain, particularly in alco-
holics. High levels of this catechol have been measured in
dopaminergic brain structures such as the substantia nigra and
the striatum (Naoi et al. 2002). Additionally, an elevated
concentration of salsolinol was found in the cerebrospinal
fluid of parkinsonian patients, and its concentration positively
correlated to the degree of motor disability and dementia
(Antkiewicz-Michaluk et al. 1997). Salsolinol has been pro-
posed as etiological factor of PD (Moser and Kompf 1992;
Antkiewicz-Michaluk et al. 2000a, b). Weiner and Collins
(1978) demonstrated that salsolinol inhibits tyrosine hy-
droxylase, a rate-limiting enzyme in dopamine synthesis,
isolated from the rat brain. Chronic administration of sal-
solinol induces the degeneration of striatal dopaminergic
neurons (Antkiewicz-Michaluk et al. 2000b). Our previous
experiments have shown that salsolinol antagonized the bio-
chemical and behavioral effects of apomorphine but did not
potentiate the cataleptogenic activity of haloperidol, as sal-
solinol displayed affinity to binding sites labeled with [H3]
apomorphine but did not displace dopamine receptor an-
tagonists (Antkiewicz-Michaluk et al. 2000a). As demon-
strated by in vitro studies, salsolinol reduces cell viability and
both BDNF- and p-CREB-mediated signal transduction pro-
tein in a dose-dependent manner. Furthermore, salsolinol in-
duces a significant increase in the activity of caspase-3 in
dopaminergic SH-SY5Y cells (Brown et al. 2013).
The aim of the present study was to examine the effects of
acute and chronic administration of salsolinol on L-DOPA-
mediated activities using both behavioral and neuro-
chemical studies in rats. To this end, we examined the effect
of salsolinol on L-DOPA-induced locomotor hyperactivity,
dopamine release in the striatum, and changes in dopamine
metabolism in different brain structures in vivo.
Materials and Methods
Animals and Treatment
The experiments were performed on male Wistar rats
whose initial body weight was 220–240 g. All animals
were provided with free access to standard laboratory food
and tap water and were maintained at room temperature
(22 C) under an artificial light/dark cycle (12/12 h, lights
on at 7 a.m.).
The rats were administered with salsolinol at a dose of
100 mg/kg intraperitoneally (i.p.) once or chronically for
14 consecutive days. In the combined treatment group, L-
DOPA (100 mg/kg i.p.) was administered once 15 min
after the final salsolinol administration. Control rats were
treated with an appropriate solvent. The rats were eutha-
nized via decapitation 2 h after the final drug injection, and
different structures of the brain were dissected. These ex-
periments were performed between 9:00 and 16:00.
All procedures were performed in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were approved by the Bioethics
Commission in compliance with Polish law. All
experimental procedures were approved by the Local
Bioethics Commission of the Institute of Pharmacology of
the Polish Academy of Sciences in Krako´w.
Drugs
Salsolinol and L-DOPA (Sigma-Aldrich, USA) were ob-
tained commercially. These compounds were dissolved in a
0.9 % NaCl solution.
Behavioral Study
Locomotor Activity
Locomotor activity was examined using actometers Opto-
Varimex activity monitors (Columbus Inst., USA) linked on-
line to a compatible IBM-PC. Each cage (43 9 44 9 25 cm)
was surrounded by a 15 9 15 array of photocell beams lo-
cated 3 cm from the floor surface as reported previously (Filip
et al. 2007). The interruptions in these photocell beams were
counted as a measure of horizontal locomotor activity, which
was defined as the distance traveled (in cm). Horizontal lo-
comotor activity was recorded for 30 min and analyzed using
Auto-Track Software (Columbus Instruments, USA). The
animals were placed in the actometers, and after 40 min of
adaptation, the animals received the specified drugs. The rats
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received salsolinol at a dose of 100 mg/kg i.p. acutely or
chronically for 14 consecutive days. Additionally, L-DOPA
(100 mg/kg i.p.) was acutely administered 15 min after sal-
solinol administration; the control group was treated with
saline. Horizontal locomotor activity was assessed for
30 min. Six animals per group were used.
Biochemical Studies
Ex Vivo Experiments
Dopamine Metabolism and L-DOPA Metabolism Two
hours after the final salsolinol injection, the rats were eutha-
nized via decapitation, and the substantia nigra and striatum
were immediately dissected. The obtained tissue was frozen
on dry ice (-70 C) until further use for biochemical assays.
Dopamine, its metabolites 3,4-dihydroxyphenylacetic acid
(DOPAC), 3-methoxytyramine (3-MT), and homovanillic
acid (HVA), and the L-DOPA metabolite 3-methoxy-DOPA
(3-MDOPA) were measured via high-performance liquid
chromatography (HPLC) using an electrochemical detection
system (Hewlett Packard 1049A). The tissue samples were
weighed and homogenized in ice-cold 0.1 M perchloroacetic
acid containing 0.05 mM ascorbic acid. After centrifugation
(10,000g, 5 min), the supernatants were filtered through RC
58 0.2-lm cellulose membranes (Bioanalytical Systems,
West Lafayette, IN, USA). The HP 1050 chromatograph
(Hewlett-Packard, Golden, CO, USA) was equipped with
C18 columns. The mobile phase consisted of 0.05 M citrate–
phosphate buffer (pH 3.5), 0.1 mM EDTA, 1 mM sodium
octyl sulfonate, and 3.5 % methanol. The flow rate was
maintained at 1 ml/min. The potential was 800 mV. Dopa-
mine and its metabolites were quantified via comparison to
the peak heights of the corresponding standards measured on
the day of analysis. Seven to ten animals per group were used.
In Vivo Microdialysis Study and Analytical Procedure
The rats were anesthetized using ketamine (75 mg/kg) and
xylazine (10 mg/kg) and secured in a stereotaxic frame (S-
toelting, USA). Vertical microdialysis guides (Intracerebral
Guide Cannula with stylet; BAS Bioanalytical, USA) were
implanted in the striatum (STR) at the following stereotaxic
coordinates: A/P ?1.0 and L/M ?2.5 from Bregma and V/D
-3.5 mm from the dura (G. Paxinos and CH Watson). On
the seventh day after surgery, the microdialysis probes were
placed inside the guides, and the striatum was perfused with
artificial cerebrospinal fluid (aCSF) consisting of 140 mM
NaCl, 2.7 mM KCl, 1.2 mM CaCl2, 1 mM MgCl2, 0.3 mM
NaH2PO4, and 1.7 mM Na2HPO4, pH 7.4, at a flow rate of
1.5 ll/min using a microinfusion pump (Stoelting, IL,
USA). Samples were collected from freely moving rats at
20 min intervals after a 3 h wash-out period. Salsolinol was
injected i.p. (acutely or chronically for 14 consecutive days)
at a 50 mg/kg dose, and the samples were collected for
180 min. In the combined treatment groups, L-DOPA
(100 mg/kg i.p.) was administered once 40 min after final
salsolinol administration. All probes were immediately
frozen on dry ice (-70 C) until use for biochemical assays.
Dopamine (DA) was measured in dialysates (20 ll) via
HPLC using an electrochemical detection system. The
HP1050 chromatograph (Hewlett-Packard, Golden, CO,
USA) was equipped with C18 columns. The mobile phase
consisted of 0.05 M citrate–phosphate buffer, pH 3.5,
0.1 mM EDTA, 1 mM sodium octyl sulfonate, and 3.5 %
methanol. The flow rate was 1 ml/min.
The chromatographic data were processed using
ChemStation software (Hewlett Packard, USA), and
dopamine and its metabolites were quantified based on
comparison to the peak height of corresponding standards
measured on the day of analysis. At the end of the
experiments, frozen slices from the brains were examined
histologically for appropriate probe placement. Six animals
per group were taken in microdialysis study.
Calculations and Statistics
Two-way analysis of variance (ANOVA) was used to de-
termine the overall significance of the behavioral assay
results (locomotor activity). Differences between the con-
trol and experimental groups were assessed using Duncan’s
test for post hoc analysis. The microdialysis data (for the
acute treatment of salsolinol) were measured via one-way
ANOVA with repeated measures. The results of chronic
administration of salsolinol were analyzed via two-way
ANOVA with repeated measures followed (if significant)
by Duncan’s test for post hoc analysis.
The results of the biochemical experiments were analyzed
via two-way ANOVA followed by Duncan’s test when ap-
propriate. The total catabolic rate of DA was assessed as the
ratio of the concentration of the final DA metabolite HVA to
that of DA and was expressed as the catabolic rate index
([HVA]/[DA]) 9 100 as previously described in detail
(Antkiewicz-Michaluk et al. 2001). This index was calcu-
lated using the concentrations in each tissue sample (n = 7).
Results
Behavioral Study
The Influence of Acute Salsolinol Administration
on L-DOPA-Induced Hyperactivity in Rats
Duncan’s post hoc test showed that acute administration
of L-DOPA (100 mg/kg i.p.) induced a significant elevation
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of horizontal locomotor activity by the rats (P \ 0.01).
However, salsolinol administered alone at a dose of 100 mg/
kg i.p. did not change their locomotor activity (Fig. 1a).
Similarly, in the combined treatment group, salsolinol did
not influence on L-DOPA-induced hyperactivity (Fig. 1a).
The Influence of Chronic Salsolinol Administration
on L-DOPA-Induced Hyperactivity in Rats
The statistical analysis demonstrated that chronic (14 days)
administration of salsolinol (100 mg/kg i.p.) did not change
the locomotor activity of rats (Fig. 1b). On the other hand,
acute injection of L-DOPA (100 mg/kg i.p.) produced a
significant elevation in horizontal locomotor activity of rats
(P \ 0.01). In the combined treatment group, multiple
treatment with salsolinol significantly (P \ 0.05) reduced
L-DOPA-induced hyperactivity (Fig. 1b).
Biochemical Studies
Ex Vivo Experiments
The Effect of Acute Salsolinol Administration on the L-
DOPA-Induced Changes in Dopamine Metabolism in Rat
Brain Structures Substantia nigra In the substantia nigra,
two-way ANOVA revealed a significant effect of treatment
with L-DOPA (F[1,27] = 21.85, P \ 0.01) on the dopamine
concentration (Table 1). However, neither the effect of sal-
solinol (F[1,27] = 0.001, N.S.) nor the interaction between
salsolinol and L-DOPA was significant (F[1,27] = 0.04,
N.S.). Duncan’s post hoc analysis demonstrated that acute
injection of L-DOPA strongly increased the concentration of
dopamine (by approximately 500 %; P \ 0.01). In contrast,
single injection of salsolinol did not alter the dopamine
concentration. Additionally, salsolinol administered in
Fig. 1 The influence of acute (a) and chronic (b) administration of
salsolinol on L-DOPA-induced changes in the locomotor activity of
rats. The rats were placed in actometers and, after 40 min of
adaptation, received the specified drugs. Salsolinol was administered
at a dose of 100 mg/kg i.p acutely (a) or chronically for 14
consecutive days (b). In the combined treatment group, L-DOPA
(100 mg/kg i.p.) was administered once 15 min after final salsolinol
administration. The control rats received a single injection of saline.
Next, the measurement was recorded for 30 min. The data are
expressed as the means ± SEM (n = 6). The data were analyzed via
two-way ANOVA followed by Duncan’s post hoc test when
appropriate. Statistical significance: *P \ 0.05, **P \ 0.01 versus
the control group; ?P \ 0.05 versus the L-DOPA-treated group
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combination with L-DOPA did not influence the L-DOPA-
induced elevation of the dopamine concentration (Table 1).
Two-way ANOVA demonstrated a significant effect of L-
DOPA (F[1,27] = 29.4, P \ 0.01) on the concentration of
DOPAC in the substantia nigra (Table 1). In contrast to this,
the effect of salsolinol (F[1,27] = 0.05, N.S.) and interac-
tion of salsolinol versus L-DOPA (F[1,27] = 0.05, N.S.)
was not significant. The post hoc analysis indicated that
acute administration of L-DOPA produced massive eleva-
tion of DOPAC concentration (approximately 6000 %;
P \ 0.01). A similar effect was observed when salsolinol
was given combined with L-DOPA (Table 1).
The statistical analysis showed significant effect of L-
DOPA (F[1,27] = 26.9, P \ 0.01) on the level of 3-MT
(Table 1). However, neither treatment with salsolinol
(F[1,27] = 0.09, N.S.) nor the interaction between sal-
solinol and L-DOPA (F[1,27] = 0.03, N.S.) was significant
(Table 1). The Duncan’s post hoc test showed that L-DOPA
induced an increase in the concentration of 3-MT (by
approximately 300 %, P \ 0.01) but that salsolinol did not
influence this effect of L-DOPA (Table 1).
In the substantia nigra, two-way ANOVA indicated a
significant effect of treatment with L-DOPA (F[1,27] = 40.8,
P \ 0.01) on the HVA concentration (Table 1). However,
neither treatment with salsolinol (F[1,27] = 0.04, N.S.) nor
the interaction between salsolinol and L-DOPA was sig-
nificant (F[1,27] = 0.04, N.S.). Post hoc analysis revealed
that L-DOPA administration strongly increased the level of
HVA (approx. 6000 %, P \ 0.01), and this effect was similar
to that in the combined treatment group (Table 1).
Two-way ANOVA demonstrated a significant effect of
L-DOPA (F[1,27] = 16.9, P \ 0.01) on the rate of dopa-
mine metabolism measured as [HVA]/[DA] (Table 1).
Statistical analysis revealed neither an effect of salsolinol
(F[1,27] = 0.001, N.S.) nor an interaction between salsoli-
nol and L-DOPA (F[1,27] = 0.001, N.S.) on [HVA]/[DA].
Duncan’s post hoc analysis demonstrated that acute admin-
istration of L-DOPA strongly increased the rate of dopamine
Table 1 The effects of acute administration of salsolinol on L-DOPA-induced changes on dopamine metabolism in rat brain structures
Treatment DA (ng/g tissue) DOPAC (ng/g tissue) HVA (ng/g tissue) [HVA]/[DA] 9 100
Acute Acute
Substantia nigra
Saline Saline 889 ± 51 212 ± 34 106 ± 15 12 ± 2
Saline L-DOPA 100 3985 ± 687** 12,888 ± 2632** 6208 ± 1000** 187 ± 39**
Salsolinol 100 Saline 773 ± 41 185 ± 14 102 ± 7 13 ± 0.8
Salsolinol 100 L-DOPA 100 4146 ± 724** 13,981 ± 1066** 5841 ± 403** 188 ± 57**

























Saline Saline 9043 ± 430 1238 ± 25 675 ± 46 7.4 ± 0.3
Saline L-DOPA 100 17,802 ± 1967* 19,266 ± 3690** 10,057 ± 1587** 57 ± 7.9**
Salsolinol 100 Saline 9457 ± 411 1573 ± 109 1017 ± 83 11 ± 0.5
Salsolinol 100 L-DOPA 100 19,351 ± 3151** 22,534 ± 2433** 10,323 ± 503** 62 ± 12**
























Salsolinol (100 mg/kg i.p.) or L-DOPA (100 mg/kg i.p.) was acutely administered (100 mg/kg i.p.). In the combined treatment group, L-DOPA
(100 mg/kg i.p.) was administered once 15 min after salsolinol administration. The rats were decapitated 2 h after injection. The concentration of
dopamine and its metabolites were measured using HPLC. The results are expressed as the means ± SEM (n = 7–10 animals per group). The
data were analyzed via two-way ANOVA followed by Duncan’s test. Statistical significance: * P \ 0.05, ** P \ 0.01 versus the control group;
? P \ 0.05, ?? P \ 0.01 versus the L-DOPA group
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metabolism (by approximately 1500 %; P \ 0.01); a similar
effect was observed when salsolinol (100 mg/kg) was
administered in combination with L-DOPA (Table 1).
Striatum
In the striatum, two-way ANOVA indicated a significant
effect of treatment with L-DOPA (F[1,27] = 17.8,
P \ 0.01) on the dopamine concentration (Table 1).
However, neither the effect of salsolinol (F[1,27] = 0.2,
N.S.) nor the interaction between salsolinol and L-DOPA
(F[1,27] = 0.07, N.S.) was significant. Duncan’s post hoc
test showed that acute administration of L-DOPA increased
the dopamine concentration (by approximately 200 %,
P \ 0.01), and acute injection of salsolinol did not alter
this effect of L-DOPA (Table 1).
Statistical analysis revealed a significant effect of L-
DOPA treatment (F[1,27] = 30.9, P \ 0.01) on the level
of DOPAC (Table 1). In contrast, neither the effect of
treatment with salsolinol (F[1,27] = 0.3, N.S.) nor the in-
teraction between salsolinol and L-DOPA (F[1,27] = 0.2,
N.S.) was significant. Post hoc analysis demonstrated that
treatment with L-DOPA induced a massive elevation in the
level of DOPAC (by approximately 1800 %). Acute ad-
ministration of salsolinol did not alter this effect of L-
DOPA (Table 1).
Two-way ANOVA demonstrated a significant effect of
acute administration of L-DOPA (F[1,27] = 53.3, P \ 0.01)
on the 3-MT concentration in the rat striatum (Table 1). In
contrast, neither the effect of salsolinol (F[1,27] = 0.3,
N.S.) nor the interaction between salsolinol and L-DOPA was
significant (F[1,27] = 1.6, N.S.). Duncan’s post hoc test
showed that acute administration of L-DOPA reduced the
level of 3-MT (by approximately 45 %). A similar effect was
observed in the combined treatment group.
Statistical analysis indicated a significant effect of L-
DOPA treatment (F[1,27] = 40.8, P \ 0.01) on the level
of HVA in the rat striatum. In contrast, neither the effect of
salsolinol (F[1,27] = 0.4, N.S.) nor the interaction be-
tween salsolinol and L-DOPA (F[1,27] = 0.001, N.S.) was
significant. Post hoc analysis demonstrated that treatment
with L-DOPA induced a strong increase in the level of
HVA (by approximately 1400 %). Salsolinol did not alter
this effect of L-DOPA (Table 1).
In the striatum, two-way ANOVA demonstrated a sig-
nificant effect of L-DOPA (F[1,27] = 29, P \ 0.01) on the
rate of dopamine metabolism measured as [HVA]/[DA]
(Table 1). Statistical analysis revealed no effect of sal-
solinol (F[1,27] = 0.2, N.S.) nor an interaction between
salsolinol and L-DOPA (F[1,27] = 0.01, N.S.) on [HVA]/
[DA]. Duncan’s post hoc analysis demonstrated that acute
administration of L-DOPA increased the rate of dopamine
metabolism (by approximately 800 %; P \ 0.01); similar
effect was observed when salsolinol (100 mg/kg) was ad-
ministered in combination with L-DOPA (by approximately
900 %) (Table 1).
The Effect of Chronic Administration of Salsolinol on the L-
DOPA-Induced Changes in Dopamine Metabolism in Rat
Brain Structures
Substantia nigra In the substantia nigra, two-way ANOVA
revealed no effect of chronic treatment with salsolinol
(F[1,24] = 2.4, N.S.) on the dopamine concentration
(Table 2). However, statistical analysis indicated a sig-
nificant effect of treatment with L-DOPA (F[1,24] = 30.1,
P \ 0.01) on the level of dopamine. The interaction be-
tween chronic administration of salsolinol and acute ad-
ministration of L-DOPA was not significant (F[1,24] = 2.8,
N.S.). Duncan’s post hoc test showed that acute adminis-
tration of L-DOPA induced an increase in the dopamine
concentration (by approximately 600 %; P \ 0.01). Addi-
tionally, in the combined treatment group, chronic admin-
istration of salsolinol (100 mg/kg) partially blocked the
L-DOPA-induced increase in the concentration of dopamine
(approximately 300 % increase; P \ 0.05) (Table 2).
Two-way ANOVA demonstrated a significant effect of
treatment with L-DOPA (F[1,24] = 43.5, P \ 0.01) on the
DOPAC concentration in the rat substantia nigra (Table 2).
However, neither the effect of chronic administration of
salsolinol (F[1,24] = 0.5, N.S.) nor the interaction between
salsolinol and L-DOPA was significant (F[1,24] = 0.5,
N.S.). Post hoc analysis revealed that L-DOPA induced a
massive increase in the DOPAC concentration (by ap-
proximately 10,000 %; P \ 0.01) and this effect was par-
tially inhibited by chronic treatment with salsolinol
(Table 2).
In the substantia nigra, statistical analysis revealed no
effect of chronic treatment with salsolinol (F[1,24] = 2.1,
N.S.) nor an interaction between chronic administration of
salsolinol and acute administration of L-DOPA (F[1,24] =
0.4, N.S.) on the level of 3-MT (Table 2). However, the
effect of treatment with L-DOPA (F[1,24] = 42, P \ 0.01)
on the 3-MT concentration was significant. Duncan’s post
hoc test showed that acute administration of L-DOPA in-
duced an increase of 3-MT concentration (by approximately
200 %; P \ 0.01). A similar effect was observed in the
combined treatment group when salsolinol (100 mg/kg)
was chronically administered followed by acute injection of
L-DOPA (by approximately 200 %; P \ 0.01) (Table 2).
Two-way ANOVA demonstrated a significant effect of
L-DOPA (F[1,24] = 233, P \ 0.01) on the HVA concen-
tration in the rat substantia nigra (Table 2). However,
neither the effect of chronic injection of salsolinol
(F[1,24] = 0.4, N.S.) nor the interaction between salsoli-
nol and L-DOPA was significant (F[1,24] = 0.4, N.S.).
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Post hoc analysis showed that L-DOPA induced a massive
increase in the HVA concentration (by approximately
6000 %; P \ 0.01); chronic treatment with salsolinol did
not alter this effect of L-DOPA (Table 2).
In the substantia nigra, two-way ANOVA demonstrated
a significant effect of L-DOPA (F[1,24] = 26.9, P \ 0.01)
on the rate of dopamine metabolism measured as [HVA]/
[DA] (Table 2). Statistical analysis revealed no effect of
chronic administration of salsolinol (F[1,24] = 0.6, N.S.)
nor an interaction between salsolinol and L-DOPA
(F[1,24] = 0.7, N.S.) on [HVA]/[DA]. Duncan’s post hoc
analysis demonstrated that acute administration of L-DOPA
strongly increased the rate of dopamine metabolism (by
approximately 2200 %; P \ 0.01), and in the combined
group, salsolinol enhanced this effect of L-DOPA
(Table 2).
Striatum
In the striatum, two-way ANOVA revealed no effect of
chronic treatment with salsolinol (F[1,24] = 1.6, N.S.) nor
any interaction between chronic administration of salsoli-
nol and L-DOPA (F[1,24] = 3.6, N.S.) on the dopamine
concentration (Table 2). In contrast, the effect of L-DOPA
treatment on the level of dopamine was significant
(F[1,24] = 25, P \ 0.01). Post hoc analysis indicated that
acute administration of L-DOPA increased the level of
dopamine (by approximately 200 %, P \ 0.01); this effect
was partially antagonized by chronic treatment with sal-
solinol (Table 2).
Two-way ANOVA demonstrated a significant effect of
L-DOPA (F[1,24] = 52.1, P \ 0.01) on the DOPAC con-
centration in the rat striatum (Table 2). In contrast, neither
the effect of chronic administration of salsolinol
(F[1,24] = 0.3, N.S.) nor the interaction between salsoli-
nol and L-DOPA was significant (F[1,24] = 0.4, N.S.).
Post hoc analysis revealed that L-DOPA induced a massive
increase in the DOPAC concentration (by approximately
2000 %; P \ 0.01); chronic treatment with salsolinol did
not alter this effect of L-DOPA (Table 2).
Statistical analysis indicated a significant effect of L-DOPA
(F[1,24] = 163, P \ 0.01) on the 3-MT concentration in the
Table 2 The effects of chronic administration of salsolinol on L-DOPA-induced changes on dopamine metabolism in rat brain structures
Treatment DA (ng/g tissue) DOPAC (ng/g tissue) HVA (ng/g tissue) [HVA]/[DA] 9 100
Chronic Acute
Substantia nigra
Saline Saline 844 ± 61 215 ± 18 152 ± 11 18 ± 2
Saline L-DOPA 100 4775 ± 898** 19,039 ± 3135** 9133 ± 622** 249 ± 60**
Salsolinol 100 Saline 913 ± 59 198 ± 14 146 ± 14 16 ± 1
Salsolinol 100 L-DOPA 100 2996 ± 623*? 5372 ± 4089**? 9256 ± 1008** 337 ± 87**

























Saline Saline 10,439 ± 308 1467 ± 49 1149 ± 31 11 ± 0.5
Saline L-DOPA 100 21,031 ± 2530** 28,780 ± 3700** 14,858 ± 719** 77 ± 10**
Salsolinol 100 Saline 11,415 ± 394 1789 ± 124 1377 ± 112 12 ± 0.8
Salsolinol 100 L-DOPA 100 16,145 ± 1655*? 24,479 ± 5854** 16,492 ± 1180** 106 ± 10**??
























Salsolinol was administered (100 mg/kg i.p.) chronically for 14 consecutive days. In the combined treatment group, L-DOPA (100 mg/kg i.p.)
was administered once 15 min after the final salsolinol administration. The rats were decapitated 2 h after the final injection. The concentration
of dopamine and its metabolites were measured using HPLC. The results are expressed as the means ± SEM of seven samples (n = 7 animals
per group). The data were analyzed via two-way ANOVA followed by Duncan’s test. Statistical significance: * P \ 0.05, ** P \ 0.01 versus the
control group; ? P \ 0.05, ?? P \ 0.01 versus the L-DOPA group
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rat striatum (Table 2). In contrast, neither the effect of chronic
injection of salsolinol (F[1,24] = 0.6, N.S.) nor the interaction
between salsolinol and L-DOPA on the level of 3-MT was
significant (F[1,24] = 1.4, N.S.). Duncan’s post hoc test
showed that L-DOPA decreased the level of 3-MT (by ap-
proximately 50 %; P \ 0.01); this effect was not altered by
chronic treatment with salsolinol (Table 2).
Two-way ANOVA showed a significant effect of treatment
with L-DOPA (F[1,24] = 432, P \ 0.01) on the HVA con-
centration (Table 1). However, neither the effect of salsolinol
(F[1,24] = 1.8, N.S.) nor the interaction between chronic
administration of salsolinol and L-DOPA was significant
(F[1,24] = 1.0, N.S.). Post hoc analysis demonstrated that
L-DOPA strongly increased the HVA concentration (by ap-
proximately 1100 %; P \ 0.01); this effect was enhanced by
chronic treatment with salsolinol (Table 2).
In the striatum, two-way ANOVA demonstrated a sig-
nificant effect of chronic administration of salsolinol
(F[1,24] = 4.5, P \ 0.05) and acute administration of L-
DOPA (F[1,24] = 128, P \ 0.01) on the rate of dopamine
metabolism measured as [HVA]/[DA] (Table 2). In con-
trast, the interaction between salsolinol and L-DOPA was
not significant (F[1,24] = 3.9, N.S.). Duncan’s post hoc
analysis demonstrated that L-DOPA induced an increase in
the rate of dopamine metabolism (by approximately
700 %); chronic administration of salsolinol significantly
enhanced this effect of L-DOPA (Table 2).
The Impact of Acute and Chronic Administration
of Salsolinol on L-DOPA Metabolism in the Rat Striatum
One-way ANOVA revealed a significant effect of treatment
(F[5,40] = 15.22, P \ 0.01) on the 3-MDOPA concen-
tration in the rat striatum (Table 3). Duncan’s post hoc test
indicated that treatment with L-DOPA induced a massive
increase in the level of 3-MDOPA (by approximately
30,000-fold; P \ 0.01); this effect was not altered by either
acute or chronic treatment with salsolinol (100 mg/kg i.p.)
(Table 3).
In Vivo Microdialysis Study
The Effects of Single Administration of Salsolinol on the L-
DOPA-Induced Changes in Dopamine Release in the Rat
Striatum
One-way repeated measures ANOVA revealed a non-sig-
nificant effect of acute administration of salsolinol
(100 mg/kg i.p.) or L-DOPA (100 mg/kg i.p.) on dopamine
release into the extracellular space (F[2,17] = 2.74, N.S.).
However, the effect of time (F[12,204] = 5.01, P \ 0.01)
and the interaction between time and treatment was sig-
nificant (F[24,204] = 3.09, P \ 0.01). Duncan’s post hoc
analysis showed that acute L-DOPA administration induced
a significant (P \ 0.05) and persistent increase in dopa-
mine release in the rat striatum (by approximately 500 %)
(Fig. 2a). However, salsolinol administered alone did not
alter the concentration of dopamine. Post hoc analysis
revealed that acute administration of salsolinol combined
with L-DOPA potentiated this effect of L-DOPA, inducing
the persistent release of dopamine (increased by up to
1200 %) (P \ 0.01) in the rat striatum (Fig. 2a).
The Effects of Chronic Administration of Salsolinol
on the L-DOPA-Induced Changes in Dopamine Release
in the Rat Striatum
Two-way repeated measures ANOVA revealed a significant
effect of treatment 2 (L-DOPA) on dopamine release
(F[1,17] = 6.73, P \ 0.05), but neither the effect of chronic
administration of salsolinol (treatment 1) (F[1,17] = 2.05,
N.S.) nor the interaction between salsolinol and L-DOPA
(F[1,17] = 2.69, N.S.) was significant (Fig. 2b). Statistical
analysis demonstrated a significant effect of time
(F[12,204] = 4.05, P \ 0.01). Additionally, the interaction
between time and treatment 1 (F[12,204] = 2.9, P \ 0.01),
between time and treatment 2 (F[12,204] = 3.67,
P \ 0.01), and between time, treatment 1, and treatment 2
(F[12,204] = 2.4, P \ 0.01) were significant. Duncan’s test
indicated that acute L-DOPA administration induced a sig-
nificant (P \ 0.01) and persistent increase in dopamine re-
lease in the rat striatum (by up to 500 %); this effect was
completely inhibited by chronic administration of salsolinol
(Fig. 2b).
Table 3 The impact of acute and chronic administration of salsolinol
on the L-DOPA-induced increase in the concentration of 3-MDOPA
in the rat striatum
Treatment 3-MDOPA (ng/g tissue)
Saline 1.31 ± 0.11
Salsolinol 100 acute 1.46 ± 0.1
Salsolinol 100 chronic 1.39 ± 0.11
L-DOPA 100 17,429 ± 2874**
Salsolinol 100 acute ? L-DOPA 100 16,046 ± 1770**
Salsolinol 100 chronic ? L-DOPA 100 15,102 ± 3278**
Effect of treatment F(5/40) = 15.22
P \ 0.01
Salsolinol was administered (100 mg/kg i.p.) acutely or chronically
for 14 consecutive days. In the combined treatment group, L-DOPA
(100 mg/kg i.p.) was administered once 15 min after the final sal-
solinol administration. The rats were decapitated 2 h after the final
injection. The concentration of 3MDOPA was measured using HPLC.
The results are expressed as the means ± SEM of six to ten samples.
The data were analyzed via one-way ANOVA followed by Duncan’s
test. Statistical significance: * P \ 0.05, ** P \ 0.01 versus the
control group; ? P \ 0.05, ?? P \ 0.01 versus the L-DOPA group
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Discussion
The pathogenesis of Parkinson’s disease (PD) is considered
to involve both environmental factors and endogenously
produced toxins, such as 1BnTIQ and, to a lesser extent,
salsolinol. The concept that salsolinol contributes to the
pathogenesis of PD arose from the observation that its
chemical structure was similar to that of MPTP, a selective
dopaminergic neurotoxin which evokes a syndrome re-
sembling the clinical profile of the disease in humans and
animals (Langston et al. 1983). In fact, our previous clin-
ical studies revealed that the concentration of salsolinol in
the CSF of patients with advanced parkinsonism was
significantly increased and that this increase correlated to
the state of dementia rather than to the progression of
parkinsonism (Antkiewicz-Michaluk et al. 1997). The lat-
ter finding was in line with studies showing that exogenous
salsolinol crossed the blood–brain barrier and interacted
with dopamine receptors in the brain (Antkiewicz-Micha-
luk et al. 2000a). Further, it was demonstrated that sal-
solinol displaced [3H]apomorphine from its binding sites
on dopamine D1 and D2 receptors at an efficacy similar to
that of dopamine, and in behavioral studies, salsolinol in-
hibited apomorphine-stimulated locomotor activity (An-
tkiewicz-Michaluk et al. 2000a). The ability of salsolinol to
interfere with the agonist binding sites on dopamine
Fig. 2 The influence of single (a) and chronic (b) administration of
salsolinol on the L-DOPA-induced changes in dopamine release.
Control samples were collected from ‘‘-60’’ to ‘‘0’’; then, salsolinol
(100 mg/kg; at time point ‘‘0’’) or L-DOPA (100 mg/kg; at time point
‘‘40’’) was administered i.p. In the combined treatment group,
salsolinol was injected 40 min before L-DOPA administration (a). As
shown in b, salsolinol was administered chronically at dose of 100
mg/kg i.p. for 14 consecutive days. In the combined treatment group,
L-DOPA (100 mg/kg i.p.) was administered once 40 min after the
final salsolinol administration. The control group was treated with
saline. Dialysates were collected every 20 min. The concentration of
dopamine was measured. The basal level of dopamine in the striatum
was 10.6 ± 3.1 pg/20 ll. The data are expressed as the means ±
SEM (n = 6). Statistical significance: *P \ 0.05, **P \ 0.01 versus
the basal level (Duncan’s test)
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receptors, thereby inhibiting their function, suggests that
this compound can attenuate dopaminergic neurotrans-
mission at sites other than those to which classical neu-
roleptics bind. In fact, the activity of salsolinol as an
endogenous neuroleptic is quite different from that of
typical neuroleptics, and even at a high dose, salsolinol did
not induce catalepsy (Antkiewicz-Michaluk et al. 2000a).
The primary finding of the present study is that chronic
administration of the endogenous compound salsolinol to
rats reversed the enhancement of L-DOPA-induced be-
havioral hyperactivity, dopamine metabolism, and dopa-
mine release in dopaminergic brain structures. The
neuroleptic-like activity of salsolinol may be responsible
for certain motor deficits observed in chronically salsoli-
noL-treated animals and for the attenuation of L-DOPA-
induced locomotor hyperactivity (Fig. 1). Biochemical
ex vivo studies showed that administration of L-DOPA
(100 mg/kg i.p.), a precursor of dopamine, causes a sig-
nificant increase in the dopamine concentration, dopamine
metabolism, and the concentration of all dopamine
metabolites in extrapyramidal brain structures, including
the substantia nigra and the striatum. Comparing the results
from the behavioral and biochemical experiments (both
ex vivo and in vivo), we concluded that salsolinol does not
always act in the same direction. A single dose of salsolinol
(100 mg/kg) did not change L-DOPA-mediated hyperac-
tivity based on the behavioral assay (Fig. 1a) as well as did
not exert any effect on the L-DOPA-mediated increase in
dopamine metabolism in the examined brain structures
(Table 1), despite significantly potentiating L-DOPA-me-
diated dopamine release in the rat striatum (Fig. 2a). These
data are in agreement with the previously described profile
of salsolinol activity in the brain. As noted above, sal-
solinol displays moderate affinity to the D1 and D2 dopa-
mine receptors and acts as an antagonist. The results of the
in vivo microdialysis experiments analyzing the influence
of salsolinol on L-DOPA-mediated dopamine release are of
particular importance. Notably, auto- and pre-synaptic D2
dopamine receptors (inhibitory receptors) are directly re-
sponsible for the regulation of the rate of dopamine
metabolism and release. Somatodendritic D2 autoreceptors
in the SN inhibit the excitability of dopamine neurons and
modulate the firing rate by activating a hyperpolarizing
potassium current (Aghajanian and Bunney 1977) and
presynaptic autoreceptors on nerve terminals (in the stria-
tum) regulate dopaminergic transmission by inhibiting
dopamine release, synthesis, and uptake (Cass and Ger-
hardt 1994; Truong et al. 2004; Seeman and Van Tol
1994). In fact, by acting as an antagonist of dopamine re-
ceptors, salsolinol may induce, potentiation of L-DOPA-
induced dopamine release. Additionally, as shown by
Homicsko et al. (2003), salsolinol can be displaced from its
binding sites by dopamine, L-DOPA, apomorphine,
benserazide, and carbidopa. Many of these displacers target
aromatic amino acid decarboxylase (AADC), although
salsolinol does not directly affect AADC activity (Toth
et al. 2002). These authors concluded that there are three
major candidates for salsolinol binding sites: AADC,
vesicular monoamine transporter, and an unidentified re-
ceptor that also displays high affinity to dopamine
(Homicsko et al. 2003; Toth et al. 2002).
Interestingly, different effects were observed after
chronic salsolinol (100 mg/kg) treatment. In the behavioral
assay (Fig. 1b) and ex vivo biochemical analysis, chronic
salsolinol administration was demonstrated to significantly
reduce the L-DOPA-induced increase in the dopamine
concentration in the substantia nigra and the striatum
(Table 2). Similarly, the DOPAC concentration was re-
duced in the animals co-treated with salsolinol and L-DOPA
in comparison to those treated with L-DOPA alone; how-
ever, the level of HVA was not different (Table 2). In that
case, the [HVA]/[DA] index, which was used as an indi-
cator of the rate of dopamine metabolism, was significantly
increased in the striatum. These results suggest that chronic
administration of salsolinol impaired both dopamine syn-
thesis and storage in neurons. The present results are in
agreement with those of our previous experiments, in which
we showed that chronic administration of salsolinol caused
moderate damage to striatal dopaminergic neurons in rats
(Antkiewicz-Michaluk et al. 2000b; Lorenc-Koci et al.
2000). Moreover, other authors have demonstrated that
salsolinol may act as an inhibitor of both tyrosine hy-
droxylase, a rate-limiting enzyme in dopamine synthesis,
(Almas et al. 1992; Minami et al. 1992) and MAO activity
(Maruyama et al. 1993). Salsolinol has also been considered
to inhibit catecholamine storage in the rat brain (Heikkila
et al. 1971) and to impair the function of vesicular mono-
amine transporter-2 (VMAT2) at dopaminergic terminals
(Naoi et al. 2004). In fact, our microdialysis study has
shown that chronic salsolinol administration, in contrast to
its acute administration, completely antagonized L-DOPA-
evoked dopamine release, suggesting that salsolinol dys-
regulated the process of dopamine storage and dopamine
release into the extracellular space (Fig. 2b). Interestingly,
the in vitro studies of other authors may partially explain the
toxic mechanism of action of salsolinol. Storch et al. (2000)
concluded that salsolinol was toxic to dopaminergic neu-
roblastoma SH-SY5Y cells by blocking the cellular energy
supply via inhibition of mitochondrial complex II activity.
Others found that incubation of SH-SY5Y cells in salsolinol
resulted in a rapid dose- and time-dependent decrease in the
intracellular level of ATP and in maximal turnover of gly-
colysis without compensating for this rapid energy deple-
tion (Morikawa et al. 1998). As recently demonstrated by
Brown et al. (2013), salsolinol exerts apoptotic effects via
caspase-3 upregulation and induces a reduction in the levels
408 Neurotox Res (2015) 27:399–410
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of BDNF and its signaling protein p-CREB. Wanpen et al.
(2004) demonstrated that salsolinol produced both apopto-
sis (by causing caspase-3 activation) and oxidative stress
(by depleting reduced GSH levels and by increasing ROS
production) in dopaminergic SH-SY5Y cells. The same
research group demonstrated that salsolinol induced DNA
damage, nuclear DNA fragmentation, decrease in TRPC1
protein levels and Ca2? influx, and this way decrease in cell
viability (Shavali et al. 2003; Bollimuntha et al. 2006).
Based on these in vitro studies it is clear that salsolinol
may act toxic on the dopaminergic neurons by complex
mechanisms. It is known that in vitro experiments are not
always in agreement with in vivo research. Generally, it
belongs to take under consideration that in vitro toxicity
can differ from in vivo obtained results, which are de-
pendent on complicated interactions among different neu-
rotransmitters in the brain. Additionally, we investigated
the effect of acute and chronic salsolinol administration on
COMT activity, which was analyzed indirectly as the
concentration of the L-DOPA metabolite 3-MDOPA, after
L-DOPA administration (Table 3). L-DOPA is well under-
stood as a direct substrate of COMT, and its metabolism
leads to the production of 3-MDOPA. COMT is responsi-
ble for both the metabolic inactivation of extraneuronal
dopamine via its conversion to 3-MT and the metabolism
of L-DOPA into 3-MDOPA (Kopin 1985; Antkiewicz-
Michaluk et al. 2001). Finally, the results of the present
study indicated that neither acute nor chronic administra-
tion of salsolinol affected COMT activity in the brain.
Combining the results of our behavioral, biochemical
ex vivo and in vivo studies, we suggest that chronic, but not
acute, administration of salsolinol disrupted the function of
dopaminergic neurons and significantly impaired the ef-
fects of L-DOPA. Therefore, we propose that an elevated
salsolinol level in parkinsonian patients may represent a
serious risk factor of the clinical efficacy of L-DOPA
therapy.
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